Barlogie, Bart

International Staging System for Multiple Myeloma

Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 2,974

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 2,632

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 2,632

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 2,575

Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma

Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell

NF-κB Signaling PathwaysMultiple Myeloma Research and Treatments

Cited by 952

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 908

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 815

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 495

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., et al. (2017) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 417

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsBone Metabolism and Diseases

Cited by 305

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., Fonseca, R., Dimopoulos, M., Shimizu, K., San Miguel, J., et al. (2008) · Blood

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 230

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Dhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 192

Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications

Miceli, M. H., Maertens, J., Buvé, K., Grazziutti, M., Woods, G., Rahman, M., Barlogie, B., & Anaissie, E. J. (2007) · Cancer

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 163

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 139

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., et al. (2021) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 128

The clinical significance of cereblon expression in multiple myeloma

Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 113

Probable Invasive Aspergillosis without Prespecified Radiologic Findings: Proposal for Inclusion of a New Category of Aspergillosis and Implications for Studying Novel Therapies

Nucci, M., Nouér, S. A., Grazziutti, M., Kumar, N. S., Barlogie, B., & Anaissie, E. (2010) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 112

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide

Badros, A. Z., Siegel, E., Bodenner, D., Zangari, M., Zeldis, J., Barlogie, B., & Tricot, G. (2002) · The American Journal of Medicine

Multiple Myeloma Research and TreatmentsThyroid Disorders and Treatments

Cited by 83

Antigen-mediated regulation in monoclonal gammopathies and myeloma

Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., et al. (2018) · JCI Insight

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 60

Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Durie, B. G., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 34

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma: A Southwest Oncology Group study

Marshall, M. E., Wolf, M. K., Crawford, E. D., Taylor, S., Blumenstein, B., Flanigan, R., Meyers, F. J., Hynes, H. E., Barlogie, B., & Eisenberger, M. (1993) · Investigational New Drugs

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 24